Ajinomoto’s fair value estimate saw a negligible increase, as both future P/E and revenue growth forecasts remained essentially unchanged.
What's in the News
- Ajinomoto and Solar Foods introduced Solein®-powered Flowering Ice Cream and other innovative products at the World Aquatics Championships in Singapore, promoting healthier and environmentally friendly snacking.
- The Solein® ingredient, produced via fermentation from microbes, offers a sustainable, nutritionally rich protein alternative for various food products.
- Ajinomoto completed a share repurchase of 14,658,600 shares (1.47% of shares outstanding) for ¥46,613.69 million, completing its buyback program announced in May 2025.
- Ajinomoto held a business briefing focused on its medical food segment.
Valuation Changes
Summary of Valuation Changes for Ajinomoto
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from ¥4125 to ¥4185.
- The Future P/E for Ajinomoto remained effectively unchanged, moving only marginally from 27.11x to 27.64x.
- The Consensus Revenue Growth forecasts for Ajinomoto remained effectively unchanged, at 5.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.